Novo Nordisk will undergo significant leadership changes, with seven board members, including chairman Helge Lund, not seeking re-election. This follows a new CEO appointment and a layoff of 9,000 staff. The company has faced profit warnings due to competition, impacting its share price. The Novo Nordisk Foundation, a major shareholder, has influenced these changes, including the removal of the former CEO. Teljes cikk (bbc.com europe)